Truist Securities Maintains Buy on Verona Pharma, Raises Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Verona Pharma and increased the price target from $38 to $44, indicating confidence in the company's future performance.
October 09, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating for Verona Pharma and increased the price target from $38 to $44, suggesting a positive outlook for the company's stock.
The increase in price target from $38 to $44 by Truist Securities, along with the maintained Buy rating, indicates a strong positive sentiment towards Verona Pharma's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100